erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the . . .treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk (file pic) . http://lm360.us/Kellenberger-daughter-of-Connelley-from-Rolla?Carbindau=132